Legal Representation
Attorney
Brian E. Turung
USPTO Deadlines
Application History
36 eventsDate | Code | Type | Description |
---|---|---|---|
May 12, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
May 12, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
Oct 24, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Oct 24, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED |
Oct 14, 2024 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION |
Oct 14, 2024 | PETG | O | PETITION TO REVIVE-GRANTED |
Oct 14, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED |
Oct 14, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
Oct 11, 2024 | EXT4 | S | SOU EXTENSION 4 FILED |
Apr 10, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Apr 9, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
Apr 9, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
Apr 9, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 13, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Oct 11, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED |
Oct 11, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 11, 2023 | EXT2 | S | SOU EXTENSION 2 FILED |
Apr 21, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Apr 20, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
Apr 19, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Apr 14, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Apr 7, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
Apr 7, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 11, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Aug 16, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
Aug 16, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Jul 27, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Jul 14, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jul 13, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Jul 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Jul 12, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Jan 12, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Jan 12, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
Jan 12, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
Jan 10, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
Sep 11, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use, namely, probiotics, for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use and baby food containing microorganisms, namely, metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal extracts sold as a component of nutritional supplements and vitamins and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome
Additional Information
Pseudo Mark
STRESS BIOTICS; STRESS PROBIOTICS
Classification
International Classes
005